How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
Guilherme Fleury Perini, Thaís Fischer, Rafael Dezen Gaiolla, Talita Bueno Rocha, Marcelo Bellesso, Larissa Lane Cardoso Teixeira, Márcia Torresan Delamain, Adriana Scheliga, Glaciano Ribeiro, Jorge Vaz Pinto Neto, Otávio Baiocchi, André Abdo, Celso Arrais‐Rodrigues, Laura Fogliatto, Ricardo de Sá Bigni, Rony Schaffel, Irène Biasoli, Juliana Pereira, Samir Nabhan, Cármino Antônio De Souza, Carlos Chiattone
Abstract
The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.